Identification and Characterization of RK22, a Novel Antimicrobial Peptide from Hirudinaria manillensis against Methicillin Resistant Staphylococcus aureus
Lu X, Yang M, Zhou S, Yang S, Chen X, Khalid M, Wang K, Fang Y, Wang C, Lai R, Duan Z (2023) · International Journal of Molecular Sciences · n=0
Study Profile
- Design
- bioinformatic discovery and synthesis of a novel antimicrobial peptide (RK22) from Hirudinaria manillensis salivary-gland transcriptome, followed by in-vitro and in-vivo antimicrobial assays against methicillin-resistant Staphylococcus aureus (MRSA); Kunming Institute of Zoology, Chinese Academy of Sciences
- Sample size (n)
- 0
- Intervention
- Synthetic RK22 peptide administered against MRSA in-vitro (MIC determination, biofilm assays) and in-vivo (mouse model)
- Comparator
- Untreated MRSA controls; comparator with LL-37 endogenous antimicrobial peptide
- Primary endpoint
- Antimicrobial activity (MIC), biofilm inhibition, in-vivo infection suppression, and safety (cytotoxicity, hemolysis, coagulation effects)
- Primary result
- RK22 showed potent anti-MRSA activity (MIC 6.25 μg/mL) including clinically resistant strain; rapid bacterial killing; inhibited biofilm formation and promoted biofilm eradication; good plasma stability; negligible cytotoxicity; minimal hemolysis; no significant pro-coagulation effects; in-vivo administration significantly inhibited MRSA infection
- Follow-up duration
- In-vivo mouse experiments (days to weeks)
- PMID
- 37686259
Key Findings
- Novel RK22 antimicrobial peptide identified from H. manillensis salivary gland transcriptome
- Potent anti-MRSA activity (MIC 6.25 μg/mL) including clinically resistant strains
- Biofilm inhibition and eradication — relevant to chronic-wound and indwelling-device infections
- Good safety profile (low cytotoxicity, minimal hemolysis, no pro-coagulation)
- In-vivo mouse efficacy demonstrated — supports advancing to GLP-toxicology and Phase-I evaluation
Limitations
- Preclinical (in-vitro + mouse) — no human data
- Mouse model does not capture all clinical complexity of MRSA disease
- Long-term toxicology, pharmacokinetics, and immunogenicity not characterized
- Resistance development potential not yet studied
- Hirudinaria manillensis is not the K040187-cleared device leech
Clinical Implications
Lu 2023 illustrates how underrepresented Asian medicinal-leech sialotranscriptomes can yield translational antimicrobial drug candidates with activity against MDR pathogens. For ASH, the study underscores that leech-pharmacology is a deep biodiversity reservoir extending beyond the established hirudin literature. No US K040187 clinical-practice implications; relevant to translational antimicrobial drug discovery.
Related Trials
Medicinal leech therapy in venous congestion of microsurgical flaps: a randomized comparison with heparin pinprick scarification
Merlino G, Carbone S, Servillo G, Marletta DA (2020)
Adjunctive medicinal leech therapy for venous congestion in free flaps: a German multicenter randomized trial
Lehnhardt M, Daigeler A, Behr B, Schmidt SV, Wallner C (2021)
Medicinal leeches and the microsurgeon: a four-year study, clinical series and risk benefit review
Whitaker IS, Josty IC, Hawkins S, Azzopardi E, Naderi N, Graf J, Damaris L, Lineaweaver WC, Kon M (2011)
Medicinal leeches for surgically uncorrectable venous congestion after free flap breast reconstruction
Pannucci CJ, Nelson JA, Chung CU, Fischer JP, Kanchwala SK, Kovach SJ, Serletti JM, Wu LC (2014)